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OBJECTIVES The purpose of this study was to determine if electron beam computed tomography (EBCT)
has potential as a cost-effective approach to diagnosis of obstructive coronary disease.
BACKGROUND Coronary calcification quantified by EBCT is closely related to the extent of atherosclerosis.
METHODS A model based upon published sensitivities (Se)/specificities (Sp) for diagnosis in an ambulatory
patient of obstructive coronary disease ($50% stenosis) and population prevalence was tested for
angiography alone, or treadmill exercise, stress echocardiography, stress thallium or predetermined
EBCT calcium score outpoints, followed by angiography if indicated.
RESULTS Total direct testing costs increased in proportion to disease prevalence whereas cost-
effectiveness, direct costs/patient diagnosed correctly with disease, decreased as a function of
prevalence. Using an EBCT calcium score of 168 (Se/Sp 5 71%/90%) provided for the least
costly and most cost-effective noninvasive pathway. Calcium scores of 80 (Se/Sp 5 84%/84%)
and 37 (Se/Sp 5 90%/77%) were also cost-effective when prevalence of disease was #70%;
but results for a .0 calcium score (Se/Sp 5 95%/46%) cutpoint were not superior to
conventional methods. Calcium score cutpoints of 37, 80 or 168 provided similar or superior
overall negative and positive predictive values to conventional noninvasive testing pathways
across all prevalence subgroups.
CONCLUSIONS In ambulatory patients evaluated for obstructive coronary disease, a testing pathway utilizing
quantification of coronary calcium by EBCT as an initial noninvasive testing approach
minimized direct costs, and maximized cost-effectiveness in population groups with low/
moderate disease prevalence (#70%); as expected, direct angiography as the first and only test
proved most cost-effective in patients with a high prevalence (.70%) of disease. (J Am Coll
Cardiol 1999;33:453–62) © 1999 by the American College of Cardiology
Spiraling health care costs and the projection of reduced
reimbursement for physician and procedural expenses have
created a cogent issue of “cost-effectiveness” resulting in
design of disease-specific diagnostic pathways and algo-
rithms. Concerns are particularly germane in the ambulatory
patient presenting de novo with possible obstructive coro-
nary disease, where the consulting physician must decide on
the most prudent diagnostic workup. The problem is to
employ a testing pathway with maximum initial triage
effectiveness, which also allows for minimization of costs.
Electron beam computed tomography (EBCT) and
quantification of coronary artery calcification have emerged
as a powerful tool to detect coronary atherosclerosis. Cor-
onary calcification is closely associated with mural athero-
matous plaque (1–3). Recent studies have demonstrated that
intramural calcium can be observed in many phases of
atherosclerotic involvement, and its presence denotes an
active process of plaque development (4). Our laboratory
and others have shown an association between EBCT
calcium content or “score” and severity or extent of luminal
coronary disease (5–9). Furthermore, the amount of calcium
correlates directly with the amount of coronary atheroscle-
rotic plaque (2,3) and the calcium “score” has potential to
identify patients at risk for cardiac events (10–12). How-
ever, an important question remains as to whether EBCT
can play a role similar to the more traditional noninvasive
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testing methods in detecting obstructive coronary artery
disease.
The purpose of the current study was to determine if an
algorithm using EBCT and the quantification of coronary
calcium, applied to a prototypic ambulatory patient popu-
lation, would have potential as an initial cost-effective
testing pathway for the diagnosis of obstructive disease. The
analysis examined application of four separate calcium
“scores” as a function of variable prevalence of obstructive
coronary disease in the population under examination and
compares results with currently established conventional
methods for invasive and noninvasive diagnosis.
METHODS
Diagnostic Testing Methods
Electron beam computed tomography. Electron beam
computed tomography has been extensively validated re-
garding noninvasive identification and quantification of
coronary calcification (2,3,5–12). Scanning is completed
within minutes, and requires minimal cooperation and no
contrast media administration. Forty consecutive, single
slice, 3-mm thick, nonoverlapping, electrocardiographically
triggered, 100-ms scans are performed. Depending on the
patient’s pulse rate, two serial breath holds may be required
to acquire scans from the root of the aorta and the origin of
the left main coronary artery through distal portions of the
right coronary artery. The appearance of high density
intramural coronary calcium deposits adjacent to low den-
sity soft tissue and surrounding fat facilitates the identifica-
tion and quantification of calcium by EBCT.
Traditional “stress testing.” The commonly applied “con-
ventional” forms of noninvasive testing for obstructive coronary
disease include treadmill exercise, stress echocardiography and
stress thallium-201. Numerous publications on each method
have established sensitivities and specificities for angiographic
diagnosis of obstructive coronary disease in an otherwise
ambulatory population. For the current comparative calcula-
tions, literature regarding traditional noninvasive methods to
diagnose “obstructive” coronary disease was consulted if the
definition of “disease” was the presence of a 50% or greater
narrowing on a subsequent coronary angiogram.
Model of Diagnostic Testing
Pathways and Direct Costs Analysis
The testing model chosen for analysis was adapted from the
original publication by Patterson et al. (13), which examined
the cost-effectiveness of four separate clinical policies for the
diagnosis of coronary artery disease as a function of the
pretest likelihood (i.e., prevalence) of disease. This model
was later extended to examine specifically the costs and
cost-effectiveness of traditional treadmill exercise, stress
thallium and positron emission tomography for the diagno-
sis of obstructive coronary disease (14). Specific equations
and detailed algorithms for these applications were provided
in the appendices of each publication and are not repeated
here.
Briefly, the current model proposed to evaluate prototypic
groups of patients presenting with a clinical history sugges-
tive of obstructive coronary disease and requiring further
evaluation. It was assumed that this was a de novo presen-
tation and that the patient was ambulatory with a normal
resting electrocardiogram without contraindications to per-
form a maximal treadmill exercise. The model would then
have the clinician, in turn, perform a single noninvasive
diagnostic test. The diagnostic pathways were: 1) a stan-
dard, graded treadmill exercise test with electrocardio-
graphic monitoring (TMET); 2) a graded exercise test
combined with rest and stress imaging with two-
dimensional echocardiography (ECHO); 3) a graded exer-
cise test combined with rest and stress imaging using
single-photon emission computed tomographic imaging
with thallium-201 (THALLIUM), or 4) an EBCT scan to
quantify the degree of coronary calcification.
A schematic of the model applied here and the testing
pathways is given in Figure 1. If the initial noninvasive test was
negative, no further testing was undertaken, and no further
direct diagnostic costs were incurred. However, if the initial
noninvasive test was deemed positive or nondiagnostic, the
patient directly underwent selective coronary angiography, for
confirmation of the diagnosis. The total initial costs for each
noninvasive pathway, as a function of disease prevalence (i.e.,
pretest likelihood), included the initial fee for the noninvasive
test (done in all patients), the cost of any complication
associated with performance of the noninvasive test, the costs
of angiography (if performed) and the costs for any complica-
tions from angiography. For comparison to noninvasive testing
strategies, a pathway that involved initial invasive angiography
alone (selective coronary arteriography [ANGIO]) was ana-
lyzed separately. Cost-effectiveness was defined as the ratio of
the total costs for any given testing pathway to the total
number of patients within that prevalence group correctly
identified with obstructive coronary disease (13,14).
Input to Costs and Effectiveness Model
Electron beam computed tomography. Application of
traditional stress testing methods have employed specific
criteria for a positive versus a negative or normal test; an
Abbreviations and Acronyms
ANGIO 5 selective coronary arteriography
EBCT 5 electron beam computed tomography




THALLIUM 5 treadmill exercise testing with thallium
scintigraphy
TMET 5 treadmill exercise testing
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example is using the development of $1 mm of horizontal
electrocardiographic ST segment depression beyond base-
line as a positive treadmill exercise response for ischemia.
Such criteria are not currently established for EBCT, but
are required for the current model. One potential criteria for
a positive EBCT study is to define this as the presence of
“any” quantifiable coronary calcium (that is, a calcium score
.0). Several studies have shown that the presence of any
coronary artery calcium detected by EBCT is highly sensi-
tive for obstructive coronary artery stenosis, albeit with a low
associated specificity (6–8). However, use of this criteria
could still provide for a cost-efficient screening test for
obstructive coronary disease. To determine an applicable
sensitivity and specificity for “any” coronary calcium (calci-
um scores .0) for input to the model, data from three
separate laboratories and patient populations were analyzed.
Listed sensitivities and specificities of a positive EBCT for
detection of a $50% stenosis on coronary angiography were
noted, and a weighted average for the three studies was
determined. The weights assigned to these calculations were
the number of patients with obstructive disease identified in
the study for sensitivity and the number of patients without
obstructive disease identified in the study for specificity (15).
Individual data from these studies are shown in Table 1. For
a calcium score .0, the weighted averaged sensitivity was
95%, and the weighted averaged specificity was 46% for at
least a 50% or greater angiographic stenosis.
Additional criteria for a positive EBCT calcium scan to
diagnose obstructive disease are available in addition to
those discussed above to provide for a comprehensive
comparison to conventional stress testing pathways. The
coronary artery calcium content or “score,” originally intro-
duced by Agatston (16), is a product of the area of
calcification (at least two contiguous pixels [2,5,6,9] with a
computed tomography density .130 Hounsfield units) per
coronary segment and a factor rated 1 through 4 dictated by
the maximum calcium density within that segment. Since
the calcium score is a continuous variable, receiver operating
characteristic analysis can be used to define sensitivity and
specificity of a variety of calcium score “cutpoints,” which
may be considered for the detection of obstructive coronary
disease by EBCT in the current model.
To assess variable EBCT coronary calcium scores and the
sensitivity and specificity for detecting obstructive coronary
disease, results from patients who underwent both EBCT
scanning and direct coronary angiography at the Mayo Clinic
were analyzed. The patient population consisted of men and
women who had no prior documented obstructive coronary
disease, most of whom had undergone prior conventional
noninvasive testing, and who had been scheduled by their
cardiologist for a diagnostic coronary angiogram. Results from
these patients and the establishment of specific values or ranges
for calcium scores as a function of angiographic disease severity
have been published previously (9).
Details of the patient population are found elsewhere (9),
but briefly 213 consecutive patients were included as part of
the analysis (152 men and 51 women, average age 50 6 9
years). Seventy-five percent (n 5 160) underwent angiog-
raphy for assessment of chest pain, 12% (n 5 25) had
abnormal stress tests but no angina, 8% (n 5 17) had
unexplained heart failure and the remainder (5%, n 5 11)
had a questionable history of prior infarction, pericarditis or
Figure 1. Schematic of cost-effectiveness model for diagnosis of
obstructive coronary artery disease. EBCT 5 electron beam
computed tomography; ECHO 5 treadmill exercise testing and
two-dimensional echocardiography; THALLIUM 5 treadmill
exercise testing with thallium scintigraphy; TMET 5 treadmill
exercise test.
Table 1. Survey of Three Previously Published Studies Using EBCT and “Any” Coronary Calcium (i.e., a Score .0) for the















Rumberger (6) 139 98% 65 39% 74
Budoff (7) 710 95% 427 44% 283
Kajinami (8) 251 91% 133 50% 118
Total or weighted
average
1,100 95% 625 46% 475
These data were used to calculate a weighted average sensitivity and specificity for input to the model (see text for details).
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unexplained dyspnea. Angiography demonstrated maximum
luminal diameter stenoses from 0 to 100%, with 47% having
“nonobstructive” disease and 53% with at least one 50% or
greater diameter stenosis. Each EBCT scan was analyzed as
previously discussed (6–8,16–18). For each study a total
(whole heart) calcium “score” was determined (16). Calcium
scores in the 213 angiographic patients ranged from 0 to
4091. The arithmetic mean calcium score was 440 6 756;
the 25th percentile was a score of 2.4 and the 75th
percentile was a score of 541.3.
Receiver operating characteristic analysis (5,6,9) was used
to establish relationships between total EBCT coronary
calcium score and the presence of at least one 50% or greater
coronary artery narrowing at angiography. In general, sen-
sitivity decreases whereas specificity increases as calcium
score increases above zero (9). Which calcium score value
and, indirectly its associated sensitivity (Se) and specificity
(Sp) for obstructive disease, would provide for comparisons
of costs and cost-effectiveness to conventional testing meth-
ods was the basis for the current investigation. To conduct
a variable sensitivity analysis, in addition to the mere
presence of coronary calcium (i.e., score .0 as discussed
above), three additional calcium score cutpoints were in-
cluded for analysis. The calcium scores chosen represent
values or ranges that are “optimal” (i.e., matched sensitivity
and specificity) versus high specificity (but moderate sensi-
tivity) versus high sensitivity (but moderate specificity).
From reference 9, these values are: a score 37 of (Se 5 90%,
Sp 5 77%), a score of 80 (“optimal” Se and Sp of 84%
respectively) and a score of 168 (Se 5 71%, Sp 5 90%).
Table 2 shows the data used for input to the model for
EBCT and the four separate calcium “scores.” Since there is no
risk to the patient for this noncontrast CT scan, the compli-
cation rate is given as 0%. A nondiagnostic scan in a patient
with normal sinus rhythm and no additional medical problems,
as is the prototypical patient for all noninvasive tests in the
current model, is unusual and estimated to be 2% at most.
Electron beam computed tomographic scanning for coronary
calcium is a limited computed tomographic scan of the chest,
without contrast, and the fee is currently $377 at our institu-
tion. Local non-Medicare fees for conventional cardiac testing,
referenced to that for EBCT, are shown on Table 2.
Conventional stress testing. Input to the model included
the fee for the initial noninvasive test, the fee for angiog-
raphy (outpatient, limited hospital stay, diagnostic only, no
ventriculography), the sensitivity and specificity for each
noninvasive test, the rate of any additional hospitalization
costs for any clinically important cardiovascular complica-
tions associated with performance of the noninvasive test or
angiography (death, ventricular fibrillation, myocardial in-
farction, cerebral infarction, vascular surgical repair, esti-
mated at $40,000/event [14]) and the nondiagnostic rate for
each test in the testing pathway. Modifications of some
input parameters from the study by Patterson (14) were
made to reflect local fees and experience. Previously pub-
lished meta-analyses or review articles were used for defi-
nition of sensitivity and specificity for TMET (15), ECHO
(19) and THALLIUM (20). Issues such as potential vari-
ations in the accuracy of exercise testing as a function of
patient gender (21), the potential for referral bias to alter
sensitivity and specificity (seen in all noninvasive tests when
compared with a “reference standard” such as angiography)
or other potentially confounding clinical factors that may
influence interpretation (e.g., hypertension) were not used
to modify the input data for the current model. Input
parameters for the model are given in Table 2 for TMET,
ECHO, THALLIUM and ANGIO.
Costs Analyses
Data for “total direct costs” represent the combined ex-
penses for the noninvasive test and any of its complications,
and for angiography and costs of its complications (if
performed). Cost-effectiveness was determined by dividing
the total direct costs at a given disease prevalence by the
number of patients correctly diagnosed with obstructive
coronary disease for that same pretest likelihood (14). Five
separate obstructive disease prevalence groups were exam-
ined; these were 0.1 (10%), 0.2 (20%), 0.5 (50%), 0.7 (70%)
and 1.0 (100%). Comparisons of the total number of
Table 2. Input to the Model (Noninvasive Testing and Angiography)
Testing Pathway Sensitivity Specificity NDR CoR Relative Fee*
TMET 68% 77% 15% 0.05% 0.8
THALLIUM 90% 77% 5% 0.05% 3.3
ECHO 84% 87% 5% 0.05% 2.5
EBCT (score .0) 95% 46% 2% 0.0% 1.0
EBCT (score 5 37) 90% 77% 2% 0.0% 1.0
EBCT (score 5 80) 84% 84% 2% 0.0% 1.0
EBCT (score 5 168) 71% 90% 2% 0.0% 1.0
ANGIO 100% 100% 0% 1.5% 7.8
*non-Medicare fee schedule relative to local fee for EBCT. Please see text for details. ANGIO 5 selective coronary
arteriography; CoR 5 rate of significant cardiovascular complications of test; EBCT 5 electron beam computed tomography
quantification of coronary artery calcification; ECHO 5 graded treadmill with stress and rest imaging using two-dimensional
echocardiography; NDR 5 nondiagnostic rate of test for obstructive coronary artery disease; THALLIUM 5 graded treadmill
with stress and rest imaging using thallium-201; TMET 5 graded exercise treadmill with electrocardiographic monitoring.
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patients with a positive noninvasive test versus angiography,
and the total number of patients correctly diagnosed for any
testing pathway were analyzed, as a function of disease
prevalence, using a one-to-one comparison of proportions.
A value of p , 0.05 was considered to achieve statistical
significance. Assuming 100 patients entering each portion
of the testing pathway, the absolute number of false nega-
tive, false positive, true positive and true negative studies
was determined for all prevalence subgroups, and the
positive and negative predictive values were calculated.
These were expressed as a percentage as: negative predictive
value 5 100 3 (total true negatives)/(true negatives 1 false
negatives), and positive predictive value 5 100 3 (total true
positives)/(true positives 1 false positives) (22).
RESULTS
Total numbers of patients undergoing angiography for
each testing pathway. The model assumed for convenience
of calculations that 100 patients in each prevalence group
underwent each of the eight testing pathways (ANGIO,
TMET, THALLIUM, ECHO, and four separate criteria for
a “positive” EBCT). Since sensitivities, specificities and non-
diagnostic rates for each of the noninvasive pathways were
variable, differences in the total number out of 100 tested who
had an abnormal test, and thus went on to coronary angiog-
raphy, would be anticipated, as dictated by model design.
Table 3 shows the number of patients out of 100 tested in each
prevalence group referred for angiography, for each of the
testing pathways. For ANGIO alone, all 100 had an invasive
procedure. As would be expected due to model design, across
all prevalence groups there were significantly fewer individuals
referred for angiography following any initial noninvasive
testing pathway than for angiography alone. There were also
differences, as a function of disease prevalence, in the numbers
of patients referred for angiography between various noninva-
sive testing pathways. At 100% disease prevalence there were
fewer patients referred for angiography using a calcium score of
168 than for any other noninvasive strategy except for TMET
and a calcium score of 80. At a prevalence of 70%, fewer
patients required angiography using a calcium score of 168 as
a threshold for a positive test than using a calcium score of .0
as a positive test. For patients with prevalence of 0.5, 0.2 and
0.1 more initial angiograms were performed for the pathway
using EBCT and a calcium score .0 as criteria for a positive
test than for any other initial noninvasive strategy. At a
prevalence of 0.7 more angiograms were done using a calcium
score .0 than for ECHO, EBCT at a score of 80, EBCT at
a score of 168 and TMET. At prevalence of 1.0, more
angiograms were done using a calcium score of .0 than for a
score of 80, for ECHO and for TMET noninvasive pathways.
Total direct costs for each testing pathway as a function
of prevalence of disease. Table 4 gives results for the
combined (total) direct costs per patient (in dollars) accord-
ing to the model for each of the seven noninvasive testing
pathways, and for ANGIO alone. The costs for angiography
alone (as per model design) were flat across the entire
prevalence range. All noninvasive testing pathways, how-
ever, showed costs that increased in direct proportion to the
prevalence of disease in the population. The lowest total
costs across all prevalence ranges was for the pathway using
an EBCT calcium score of 168. For prevalence groups of
0.1, 0.2, 0.5 and 0.7, the pathways using an EBCT calcium
score of 80, an EBCT calcium score of 37, TMET, ECHO,
THALLIUM (except at prevalence of 0.7) and an EBCT
score .0 were, respectively, the second, third, fourth, fifth
and sixth least costly noninvasive pathways. At a prevalence
of 1.0 ANGIO as an initial testing strategy involved less
total costs than the noninvasive pathways, except for
TMET and an EBCT calcium score of 168.
Number of patients correctly diagnosed with obstructive
disease for each pathway. Table 5 shows the absolute
number of patients (out of 100 tested) for each prevalence
group who had a correct diagnosis of obstructive disease at
the end of any one of the eight testing pathways. The “true
positive rate” is given in parentheses next to each absolute
number. For disease prevalence of 0.7 or less, the number of
patients in each testing pathway diagnosed using an initial
Table 3. Number of Patients out of 100 in Each Prevalence Group and for Each Testing
Pathway Undergoing Angiography Directly or for a Positive or Nondiagnostic Noninvasive Test
Testing Pathway
Prevalence of Obstructive Disease in Population (% 3 1022)
0.1 0.2 0.5 0.7 1.0
TMET 38*†‡ 42*†‡ 54*‡ 61*‡ 73*‡
THALLIUM 33*†‡ 40*†‡ 59*†‡ 71* 91*†§
ECHO 27*‡ 34*‡ 53*‡ 66*‡ 85*†‡
EBCT (score .0) 59*† 63*† 75*† 83*† 95†
EBCT (score 5 37) 32*‡ 38*‡ 58*†‡ 71* 90*†
EBCT (score 5 80) 25*‡ 32*‡ 52*‡ 65*‡ 84*‡
EBCT (score 5 168) 19*‡ 25*‡ 42*‡ 54*‡ 72*‡
ANGIO 100 100 100 100 100
*p , 0.05 versus angiography alone. †p , 0.05 versus EBCT (score 5 168). ‡p , 0.05 versus EBCT (score .0). §p , 0.05
versus TMET. Abbreviations as in Table 2.
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noninvasive strategy was not proportionally different than
the number diagnosed by angiography alone. The only
exceptions were at a prevalence of 0.7 (as with a prevalence
of 1.0), where proportionally fewer patients had a correct
diagnosis by undergoing TMET or use of an EBCT score
of 168 than any other noninvasive or invasive testing
pathway. At a disease prevalence of 1.0 (100%), fewer
patients had a correct diagnosis by undergoing any nonin-
vasive test first rather than proceeding directly to angiogra-
phy. The only exception was for an EBCT calcium score .0
as criterion for a positive test, where 95 out of 100 would
have been referred for angiography.
Cost-effectiveness for each testing pathway. Table 6
gives the “cost-effectiveness” in dollars per patient correctly
diagnosed with obstructive disease for each testing pathway.
These data are the total direct costs given in Table 4 divided
by the corresponding absolute number of patients correctly
diagnosed for each prevalence and pathway as given in
Table 5. These costs, rather than progressively increasing, as
for total direct costs (Table 4), decreased as prevalence of
disease rose from 0.1 to 1.0. For prevalence of disease #0.7,
examinations using EBCT with a score of 168, a score of 80
or a score of 37 were generally the first, second and third
most cost-efficient initial diagnostic testing pathways, re-
spectively. These were followed in order by TMET as
fourth, ECHO as fifth and THALLIUM as sixth. The
testing pathway using an EBCT calcium score .0 was
actually the least cost-efficient of the noninvasive testing
strategies. However, in the highest prevalence group (.70%
with obstructive disease), initial angiography with no prior
noninvasive testing became the most cost-effective strategy
for the diagnosis of obstructive coronary artery disease.
Negative and positive predictive values of each testing
pathway. Tables 7 and 8 show the calculated negative and
positive predictive values for the combined noninvasive/
angiography testing pathways as compared with the use of
angiography alone. By study design, angiography was the
reference standard for obstructive disease and thus has both
100% negative and 100% positive predictive values. In
general for the initial noninvasive strategies, negative pre-
dictive value (as expected) decreased as disease prevalence
increased in the population undergoing testing. Just the
opposite was seen for positive predictive value as a function
of prevalence.
For low prevalence (0.1 and 0.2), the negative predictive
value of all testing pathways was very high, ranging from
Table 4. Total Combined Costs per Patient for Each of the Eight Diagnostic Testing Pathways
as a Function of Prevalence of Coronary Artery Disease in the Population Tested
Testing Pathway
Prevalence of Obstructive Disease in Population (% 3 1022)
0.1 0.2 0.5 0.7 1.0
TMET $1,660 $1,802 $2,228 $2,476 $2,902
THALLIUM $2,411 $2,659 $3,333 $3,759 $4,469
ECHO $1,913 $2,161 $2,835 $3,297 $3,971
EBCT (score .0) $2,470 $2,612 $3,038 $3,321 $3,748
EBCT (score 5 37) $1,512 $1,725 $2,435 $2,896 $3,570
EBCT (score 5 80) $1,264 $1,512 $2,222 $2,683 $3,357
EBCT (score 5 168) $1,051 $1,264 $1,867 $2,293 $2,931
ANGIO $3,540 $3,540 $3,540 $3,540 $3,540
See text for details. Abbreviations as in Table 2.
Table 5. Percentage of Patients Correctly Diagnosed (True Positive Rate) and Absolute Number
(in Parentheses) With Obstructive Coronary Disease out of 100 Tested in Each Prevalence
Group at Completion of Any Testing Pathway
Testing Pathway
Prevalence of Obstructive Disease in Population (% 3 1022)
0.1 0.2 0.5 0.7 1.0
TMET 70% (7) 75% (15) 72% (36) 73% (51*) 73% (73*)
THALLIUM 90% (9) 90% (18) 90% (45) 90% (63) 91% (91*†‡)
ECHO 90% (9) 85% (17) 86% (43) 86% (60) 85% (85*†)
EBCT (score .0) 100% (10) 95% (19) 96% (48) 96% (67) 95% (95†‡)
EBCT (score 5 37) 90% (9) 90% (18) 90% (45) 90% (63) 90% (90*†‡)
EBCT (score 5 80) 80% (8) 85% (17) 84% (42) 84% (59) 84% (84*)
EBCT (score 5 168) 70% (7) 70% (14) 72% (36) 71% (50*) 72% (72*)
ANGIO 100% (10) 100% (20) 100% (50) 100% (70) 100% (100)
*p , 0.05 versus angiography alone. †p , 0.05 versus EBCT (score 5 168). ‡p , 0.05 versus TMET. All others, p 5 NS versus
EBCT (score 5 168). Abbreviations as in Table 2.
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91% to 100%. For the initial noninvasive testing and
intermediate (0.5) or higher prevalence of disease, use of an
EBCT score .0 showed the highest negative predictive
value followed in order by an EBCT score of 37, THAL-
LIUM, ECHO, EBCT score of 80, EBCT score of 168
and TMET. Except for these latter two testing pathways,
these values ranged from 83% to 92%. The negative pre-
dictive value of all tests except angiography fell off precipi-
tously as prevalence approached 0.7 or greater; this is
reflective of the dominance of true coronary disease in that
population.
For the noninvasive testing pathways, the positive pre-
dictive value, up to disease prevalence of 0.7, was generally
highest using an EBCT score of 168, but was in general
quite poor when prevalence was low. Overall, positive
predictive values were very similar for ECHO and an
EBCT score of 80, followed in order by an EBCT score of
37, THALLIUM and TMET.
DISCUSSION
Seven different noninvasive testing pathways and one
involving coronary angiography alone were evaluated in a
model that examined initial diagnostic costs of prototypic
ambulatory, symptomatic patients undergoing de novo
evaluation for obstructive coronary disease. The major
aims of the analyses were assessment of total diagnostic
workup costs, cost-effectiveness and the overall predictive
values of the various testing pathways, as a function of
prevalence (pretest likelihood) of disease. Several conclu-
sions can be drawn based upon the results presented.
First, three out of the four EBCT models (calcium score
of 168, score of 80 and score of 37, respectively) were the
least costly of the eight pathways examined for the
diagnosis of obstructive coronary disease, across all prev-
alence groups. However, the EBCT model using a score
.0 (i.e., any calcium) was actually the most costly, except
for direct ANGIO alone. Second, these same three least
costly EBCT pathways were also the most cost-effective
for low (0.1, 0.2) and moderate (0.5, 0.7) prevalence
groups. The negative predictive values, regardless of the
noninvasive pathway chosen, were very high for low
prevalence groups but fell precipitously as prevalence
increased to moderate (0.5, 0.7) and high (1.0) values.
Pathways using EBCT and calcium scores cutpoints of
168, 80 and 37 had negative predictive values comparable
to the more expensive diagnostic paths of ECHO,
THALLIUM and ANGIO. Positive predictive values
were low for all paths at low prevalence and increased as
prevalence increased. The same three pathways using
EBCT provided positive predictive values, however,
Table 6. “Cost-Effectiveness” (Total Direct Costs in Dollars per Patient Correctly Diagnosed
With Obstructive Coronary Artery Disease) for the Individual Diagnostic Testing Pathways
Testing Pathway
Prevalence of Obstructive Disease in Population (% 3 1022)
0.1 0.2 0.5 0.7 1.0
TMET $23,717 $12,014 $6,189 $4,855 $3,975
THALLIUM $26,787 $14,773 $7,407 $5,966 $4,910
ECHO $21,255 $12,713 $6,594 $5,494 $4,671
EBCT (score .0) $24,703 $13,748 $6,329 $4,957 $3,944
EBCT (score 5 37) $16,804 $ 9,584 $5,410 $4,596 $3,966
EBCT (score 5 80) $15,800 $ 8,896 $5,290 $4,547 $3,996
EBCT (score 5 168) $15,016 $ 9,028 $5,186 $4,587 $4,071
ANGIO $35,400 $17,700 $7,080 $5,057 $3,540
See text for details. Abbreviations as in Table 2.
Table 7. Negative Predictive Value of Testing Pathway as a Function of Prevalence of Disease
in the Population Tested
Testing Pathway
Prevalence of Obstructive Disease in Population (% 3 1022)
0.1 0.2 0.5 0.7 1.0
TMET 95% 91% 70% 51% 0%
THALLIUM 98% 97% 88% 76% 0%
ECHO 99% 95% 85% 71% 0%
EBCT (score .0) 100% 97% 92% 82% 0%
EBCT (score 5 37) 99% 97% 88% 76% 0%
EBCT (score 5 80) 97% 96% 83% 69% 0%
EBCT (score 5 168) 96% 92% 76% 56% 0%
ANGIO 100% 100% 100% 100% 100%
Abbreviations as in Table 2.
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comparable to those of the THALLIUM and ECHO
noninvasive pathways. Third, when the prevalence of
disease in the population was high (exceeding 0.7 or
70%), the least costly, maximum cost-effective and most
predictive pathway for the establishment of obstructive
coronary disease was direct invasive angiography, with no
prior noninvasive studies.
Limitations. There are several limitations of the current
presentation. First, the analysis was “theoretical”; that is,
conclusions were not based upon prospective clinical inves-
tigations comparing EBCT, THALLIUM, ECHO,
TMET and ANGIO, but on a mathematical model. The
current model does not provide input for secondary param-
eters derived from traditional noninvasive studies such as
duration of exercise, heart rate modulation, blood pressure
response, incidence of dysrhythmias with exercise or in-
creased thallium-201 lung uptake. Such data provide im-
portant prognostic information, but do not enter into an
analysis examining solely costs of the initial diagnostic
workup. Thus confirmation remains via direct clinical com-
parisons. Certainly a “late” positive stress test may have
different clinical implications from an “early” positive stress
test, but a diagnosis of obstructive coronary disease would
remain unchanged. The current computer model data,
however, do provide a framework for obligatory clinical
investigations. Second, the analysis examined direct diag-
nostic costs only and did not consider additional, albeit less
tangible parameters. Thus, the potential for additional costs
as a consequence of delaying the diagnosis of obstructive
disease was not included as an outcome for an initially
falsely negative noninvasive test. The initial model proposed
by Patterson and colleagues (13,14) also estimated changes
in quality of life in subjects, both with and without a correct
diagnosis of coronary artery disease at completion of testing.
Additional issues along these lines to estimate additional
indirect costs associated with different (long-term) clinical
outcomes were not presented here. Although the model is
robust, and these calculations could have been incorporated,
they required additional theoretical (and more tenuous)
estimates, which were not the primary objective of this
direct costs economic analysis.
Third, only prespecified EBCT calcium score cutpoints
were examined. Electron beam computed tomography coro-
nary calcium scores of .0, 37, 80 and 168 were used as
thresholds for a positive test in the sensitivity analysis. Patients
with scores of ,168, ,80, ,37 or even no coronary calcium
would be called “negative” within their respective testing
pathways, and yet, as pointed out by prior studies, may still
have coronary plaque disease (2,3). The cutpoint of 80 was
chosen because it resulted in maximizing both sensitivity and
specificity based upon 213 clinical studies comparing EBCT
calcification and maximal luminal stenoses seen at angiography
(9). Two additional EBCT cutpoints were chosen to allow
analysis of thresholds with either a high sensitivity and mod-
erate specificity (calcium score of 168) or a high sensitivity and
moderate specificity (calcium score of 37) (9). The calcium
score of .0, demonstrating the highest overall sensitivity
(95%) but lowest overall specificity (46%) for any noninvasive
test, was actually one of the most expensive pathways. Objec-
tive and subjective guidelines for negative and positive tests are
also applied using the more traditional forms of noninvasive
cardiac testing. The development of 1-mm or more horizontal
ST segment depression beyond baseline is commonly used to
define a “positive” TMET. If the amount of ST depression is
below this threshold, the test is termed “negative” although the
patient may, in fact, have disease. Analogous criteria are used
to define a positive stress echocardiogram or a positive stress
thallium. Here subjective, operator-dependent parameters,
such as changes in regional wall motion (stress echocardiogra-
phy) or visual assessment of radioisotope uptake (stress thalli-
um), are often used in clinical decision making. However, these
criteria are based on application of these techniques across an
extensive clinical spectrum representing a large number of
patients. Such broad clinical application and experience is not
available using EBCT. Although calculation of the total
calcium score using EBCT is quantitative (2,3,8–11) and
operator independent (23), reproducibility varies (24,25) de-
pending on the laboratory. Thus it is possible with application
of EBCT to these purposes that alternative calcium scores,
Table 8. Positive Predictive Value of Testing Pathways as a Function of Prevalence of Disease in
the Population Tested
Testing Pathway
Prevalence of Obstructive Disease in Population (% 3 1022)
0.1 0.2 0.5 0.7 1.0
TMET 18% 36% 67% 84% 100%
THALLIUM 27% 45% 76% 89% 100%
ECHO 33% 50% 81% 91% 100%
EBCT (score .0) 17% 30% 64% 81% 100%
EBCT (score 5 37) 28% 47% 78% 89% 100%
EBCT (score 5 80) 32% 53% 81% 91% 100%
EBCT (score 5 168) 36% 56% 86% 93% 100%
ANGIO 100% 100% 100% 100% 100%
Abbreviations as in Table 2.
460 Rumberger et al. JACC Vol. 33, No. 2, 1999
Costs and Effectiveness of EBCT for CAD February 1999:453–62
particularly for the most cost-efficient values of 37, 80 or 168,
may prove to be more appropriate in clinical practice.
Fourth, the fees used for determination of costs were
based upon current clinical charges at our institution, which
includes a large, Midwest primary cardiology and referral
practice. These are reflective of regional fees and should be
interpreted cautiously to other practices in which fees for
traditional diagnostic cardiac testing are higher or lower.
Limitations of the presentation also relate to comparisons
with the more traditional stress testing methods. The values
of sensitivity and specificity cited for these examinations
were based upon current literature and reflect studies that
involved large numbers of patients and also were either
reviews or meta-analyses. However, these conventional
forms of stress testing also have limitations when applied to
the general adult population. In the current model, all
members of the populations studied, regardless of preva-
lence, were assumed to have normal resting electrocardio-
grams, to be ambulatory and to be able to undergo maximal
treadmill exercise using an appropriate graded stress proto-
col. This is not the case in all patients who may present de
novo to a clinician with symptoms suggesting exercise-
induced ischemia. Stress electrocardiography, with or with-
out imaging with radionuclides or two-dimensional echo-
cardiography, relies on inducible limitations of blood flow to
the myocardium in association with “physiologically” signif-
icant coronary obstructive disease. However, a 50% or
greater stenosis on angiography may or may not be sufficient
to result in myocardial ischemia or inducible regional wall
motion abnormalities with increased demand. In addition,
medications, particularly beta-adrenergic blocking agents,
may reduce the probability to correctly identify the potential
for ischemic disease. Electron beam computed tomography
on the other hand, examines the extent of disease based
upon anatomic information. It is not surprising that the
receiver operating characteristic curve areas for EBCT and
obstructive coronary disease reported in prior publications
from our laboratory (5,6,9) and elsewhere (7) show very
high areas under the curves, since they compare associations
between atherosclerotic plaque and angiographic anatomy.
Furthermore, EBCT scanning can be done regardless of
resting electrocardiographic abnormalities, regardless of the
presence of cardiotonic medications used to treat hyperten-
sion or other noncardiac conditions and regardless of the
individual’s ability to perform a maximum stress test.
Recommendations. The current study provides data that
support the application of EBCT and quantification of
coronary artery calcification as a minimum cost and maxi-
mum effectiveness approach to the diagnosis of obstructive
coronary disease in specific subsets of the general popula-
tion. These data should be interpreted as reflecting only the
short-term economics for the diagnosis of coronary disease
in a large regional cardiology practice. Furthermore, they are
not meant to impugn the value of physiologic testing for
obstructive disease or potential for localization of ischemia
to specific anatomic sites, as these studies clearly add
information on patient prognosis and response to therapy.
Additionally, the analyses were theoretical, being calculated
from a computer model, and limited to evaluation of initial
diagnostic workup costs only. Issues of long-term consider-
ations regarding outcomes and quality of life issues were
intentionally not incorporated into the model. Based upon
the data presented, use of “any” coronary calcium by EBCT
(excellent sensitivity, low specificity) as an initial screening
test for obstructive coronary disease in the ambulatory
symptomatic patient, although demonstrating the highest
negative predicative value of any initial noninvasive pathway
regardless of disease prevalence, was more costly and less
cost-effective than TMET, ECHO or THALLIUM. The
least costly and most cost-efficient pathway was use of a
calcium score of 168. This was associated with a high
specificity (90%) and a moderate sensitivity (77%). The
results, however, were quite similar to those of a score of 80,
with both a high sensitivity and specificity (84% for both).
Overall, the negative and positive predictive values of using
a calcium score of 80 as a positive test were comparable to
THALLIUM and ECHO, across all prevalence groups,
and thus diagnostic accuracy may not be compromised by
using this moderate calcium score value. Direct clinical
application, however, would be required to examine the
value of any calcium score as compared with conventional
methods of diagnosing obstructive coronary disease. Cal-
cium scores of 100 or greater have been shown to provide
information regarding the medium-term prognosis for car-
diac events in symptomatic (10) and asymptomatic (11,12)
individuals, thus suggesting that a moderate calcium score
may have diagnostic, as demonstrated herein, as well as
prognostic potential in symptomatic, ambulatory individuals
undergoing evaluation for obstructive coronary disease. As
anticipated, direct coronary angiography with no prior
noninvasive testing in the highest prevalence groups was
actually the most cost-effective approach to diagnosis of
obstructive coronary disease. Specific recommendations for
other subsets of the general adult population not included in
the analyses and the potential influences of geographic
differences in fee schedules for noninvasive tests and angiog-
raphy will await extension of the principles put forward here
into the clinical environment.
Reprint requests and correspondence: Dr. John A. Rumberger,
Diagnostic Cardiovascular Consultants, Inc., Suite 1400, Colum-
bus, Ohio 43215.
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